Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 13:19:239-254.
doi: 10.2147/TCRM.S379673. eCollection 2023.

Congenital Athymia: Unmet Needs and Practical Guidance

Affiliations
Review

Congenital Athymia: Unmet Needs and Practical Guidance

Evey Howley et al. Ther Clin Risk Manag. .

Abstract

Inborn errors of thymic stromal cell development and function which are associated with congenital athymia result in life-threatening immunodeficiency with susceptibility to infections and autoimmunity. Athymic patients can be treated by thymus transplantation using cultured donor thymus tissue. Outcomes in patients treated at Duke University Medical Center and Great Ormond Street Hospital (GOSH) over the past three decades have shown that sufficient T-cell immunity can be recovered to clear and prevent infections, but post-treatment autoimmune manifestations are relatively common. Whilst thymus transplantation offers the chance of long-term survival, significant challenges remain to optimise the outcomes for the patients. In this review, we will discuss unmet needs and offer practical guidance based on the experience of the European Thymus Transplantation programme at GOSH. Newborn screening (NBS) for severe combined immunodeficiency (SCID) and routine use of next-generation sequencing (NGS) platforms have improved early recognition of congenital athymia and increasing numbers of patients are being referred for thymus transplantation. Nevertheless, there remain delays in diagnosis, in particular when the cause is genetically undefined, and treatment accessibility needs to be improved. The majority of athymic patients have syndromic features with acute and chronic complex health issues, requiring life-long multidisciplinary and multicentre collaboration to optimise their medical and social care. Comprehensive follow up after thymus transplantation including monitoring of immunological results, management of co-morbidities and patient and family quality-of-life experience, is vital to understanding long-term outcomes for this rare cohort of patients. Alongside translational research into improving strategies for thymus replacement therapy, patient-focused clinical research will facilitate the design of strategies to improve the overall care for athymic patients.

Keywords: DiGeorge syndrome; SCID; athymia; immunodeficiency; quality of life; rare diseases; thymus transplantation.

PubMed Disclaimer

Conflict of interest statement

Dr E Graham Davies reports personal fees from Videregen Limited, Leeds, UK, outside the submitted work. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Optimising outcomes for patients with congenital athymia: Diagram reflecting the layering of patient-centred practical guidance to systematically and comprehensively address the challenges encountered and unmet needs experienced by athymic patients.

References

    1. Kreins AY, Maio S, Dhalla F. Inborn errors of thymic stromal cell development and function. Semin Immunopathol. 2021;43(1):85–100. doi: 10.1007/s00281-020-00826-9 - DOI - PMC - PubMed
    1. Markert ML, Gupton SE, McCarthy EA. Experience with cultured thymus tissue in 105 children. J Allergy Clin Immunol. 2022;149(2):747–757. doi: 10.1016/j.jaci.2021.06.028 - DOI - PMC - PubMed
    1. Davies EG, Cheung M, Gilmour K, et al. Thymus transplantation for complete DiGeorge syndrome: European experience. J Allergy Clin Immunol. 2017;140(6):1660–70 e16. doi: 10.1016/j.jaci.2017.03.020 - DOI - PMC - PubMed
    1. Markert ML, Kostyu DD, Ward FE, et al. Successful formation of a chimeric human thymus allograft following transplantation of cultured postnatal human thymus. J Immunol. 1997;158(2):998–1005. doi: 10.4049/jimmunol.158.2.998 - DOI - PubMed
    1. Kreins AY, Bonfanti P, Davies EG. Current and future therapeutic approaches for thymic stromal cell defects. Front Immunol. 2021;12:655354. doi: 10.3389/fimmu.2021.655354 - DOI - PMC - PubMed